Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Trastuzumab Benefits Women with Locally Advanced or Inflammatory Breast Cancer
(Posted: 03/15/2010, Updated: 04/07/2014) - Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, according to a study published in the January 30, 2010, Lancet.
- Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
(Posted: 03/12/2014) - In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rituximab (Rituxan®) lived substantially longer without their disease getting worse than patients who received a placebo plus rituximab. Overall survival was also improved in patients who received idelalisib plus rituximab. Patients who received idelalisib and rituximab were also more likely to live 12 months after beginning treatment and to have their cancer regress compared with patients who received a placebo plus rituximab.
- Combination of Obinutuzumab Plus Chlorambucil Improves Survival in Patients with Chronic Lymphocytic Leukemia and Other Health Conditions
(Posted: 02/21/2014) - In an international randomized phase III trial, previously untreated patients with chronic lymphocytic leukemia and other health conditions who received a combination of obinutuzumab (Gazyva™) and chlorambucil (Leukeran®) lived longer without their disease getting worse (progression-free survival) and had better overall survival than patients who received chlorambucil alone.
- Combination of Nab-Paclitaxel and Gemcitabine Improves Survival in Patients with Metastatic Pancreatic Cancer
(Posted: 11/15/2013) - In an international randomized phase III trial, patients with metastatic pancreatic cancer who were treated with a combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived longer than patients who were treated with gemcitabine alone. Patients who received both drugs also lived longer without their disease getting worse (progression-free survival).
- Pomalidomide plus Low-Dose Dexamethasone Improves Survival for Patients with Multiple Myeloma
(Posted: 09/19/2013) - Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed (worsened) despite other treatments. Patients who received the combination therapy lived longer without the disease getting worse than patients who received high-dose dexamethasone alone. Overall survival was also improved in the group that received the combination therapy compared with the other group.